Strategic capabilities New Perspectives, Inc. specializes in operationalizing transformation for emerging pharma and biotech firms, offering end-to-end support from strategy to market launch. This presents a sales opportunity to position them as a turnkey partner for companies seeking rapid, commercially-ready organization development and asset packaging for licensing or sale.

Experience leverage With a track record spanning over 42 products launched across 32 therapeutic areas and more than $20 billion in peak annual revenue, the firm can credibly support asset optimization, investment attraction, and regulatory pathway guidance, appealing to startups and mid-sized biotechs aiming to de-risk and accelerate commercialization.

End-to-end embedding Their value proposition includes embedding an in-house team member within client organizations to drive momentum and ensure smooth ownership transition. This opens opportunities for retained advisory and interim leadership services during critical development phases and post-launch scaling.

Asset breadth Experience spans NCEs, 505(b)(2), rare and orphan drugs, generics, devices, and biosimilars, enabling cross-segment cross-sell across multiple asset types. This suggests upsell potential to clients with diverse portfolios seeking tailored commercial strategies and lifecycle planning.

Growth readiness Client profile skews toward emerging pharma and biotech firms in need of commercialization readiness, investment packaging, and exit strategies. There is an opportunity to expand services around market access, payer strategy, and licensing negotiations, aligning with clients’ near-term growth and exit timelines.